Technology
Health
Biotechnology

Alimera Sciences

$1.11
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.05 (-4.31%) Today
-$0.05 (-4.31%) Today

Why Robinhood?

You can buy or sell ALIM and other stocks, options, ETFs, and crypto commission-free!

About

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. Read More The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

Employees
124
Headquarters
Alpharetta, Georgia
Founded
2003
Market Cap
81.29M
Price-Earnings Ratio
5.39
Dividend Yield
0.00
Average Volume
127.96K
High Today
$1.15
Low Today
$1.11
Open Price
$1.15
Volume
38.37K
52 Week High
$1.21
52 Week Low
$0.7181

Collections

Technology
Health
Biotechnology
Research And Development
Biopharmaceutical
Pharmaceutical
US
North America

News

Markets InsiderMar 14

EyePoint Pharmaceuticals Reports Fiscal Period Ended December 31, 2018 Financial Results and Highlights Recent Clinical and Operational Developments

-YUTIQ™ and DEXYCU™ commercially launched in 1Q2019- -$60 million debt facility secured to support YUTIQ and DEXYCU commercial launches- -Conference call and webcast today, March 14, at 8:30 a.m. ET- WATERTOWN, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today reported financial results for the three and six-month fiscal period ended December 31,...

26
Yahoo FinanceMar 6

Alimera Sciences Announces the Reimbursement of ILUVIEN(R) in France

France is a Significant Market for Intravitreal Steroid Use ATLANTA, GA / ACCESSWIRE / March 6, 2019 / Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that its subsidiary, Alimera Sciences Limited, received a positive resolution for the pricing and reimbursement approval for ILUVIEN® from Comité Economique des Produits de Santé (CEPS). This means that in France, ILUVIEN will be fully reimbursed for use in...

84
MarketBeatMar 1

Stock Price, News, & Analysis for Alimera Sciences

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in...

4

Earnings

-$0.11
-$0.08
-$0.05
-$0.02
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 1
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.